PF-07284892 in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT04800822. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Study identification
- NCT ID
- NCT04800822
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 53 participants
Conditions and interventions
Conditions
Interventions
- PF-07284892 Drug
- binimetinib Drug
- cetuximab Biological
- encorafenib Drug
- lorlatinib Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 16, 2021
- Primary completion
- Jun 18, 2024
- Completion
- Jun 18, 2024
- Last update posted
- Oct 21, 2024
2021 – 2024
United States locations
- U.S. sites
- 19
- U.S. states
- 8
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona - Phoenix | Phoenix | Arizona | 85054 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| California Cancer Associates for Research and Excellence | Encinitas | California | 92024 | — |
| California Cancer Associates for Research and Excellence | San Marcos | California | 92069 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Brigitte Harris Cancer Pavilion | Detroit | Michigan | 48202 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| START Midwest | Grand Rapids | Michigan | 49546 | — |
| Henry Ford Medical Center - Columbus | Novi | Michigan | 48377 | — |
| Mayo Clinic in Rochester, Minnesota | Rochester | Minnesota | 55905 | — |
| Memorial Sloan Kettering Cancer Center David H Koch Center for Cancer Care | New York | New York | 10021 | — |
| Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavilion | New York | New York | 10022 | — |
| Tennessee Oncology PLLC | Franklin | Tennessee | 37067 | — |
| Tennessee Oncology, PLLC | Franklin | Tennessee | 37067 | — |
| Sarah Cannon Research Institute- Pharmacy | Nashville | Tennessee | 37203 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology PLLC | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04800822, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 21, 2024 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04800822 live on ClinicalTrials.gov.